Risk 6Growth 4Exponential 2Fair value $12 $8.5–$15
The 20-second read
What it does
Ecovyst Inc. (NYSE: ECVT) is a specialty-chemicals company headquartered in Malvern, Pennsylvania — founded in 1831, renamed from PQ Group Holdings in August 2021, IPO 2017, CEO Kurt J.
Where it stands
$11.81 · Watch · fair value ~$12 (+2% vs price) · Risk 6/10, Growth 4/10
Where it's going
A newly de-levered sulfuric-acid and catalyst franchise at ~13x FY27 earnings with a 6.7% FCF yield — it gets interesting on a base near the 200-DMA (~$11) once the Aug-6 print confirms gross margin has stopped sliding; it breaks if margins keep compressing and the Street's $9.67 target proves right rather than stale.
$9.67 (high $10 / low $9; 4 Buy · 2 Hold) — targets sit 18% below the price despite Buy ratings; almost certainly stale after the 12-mo run — context, not our anchor
2/10 · Low — growth decelerates to 4–6% after the FY26 portfolio-reshaping step; a self-help industrial, not an exponential
Technicals
Weak near-term — $11.81 is 12% below the 50-DMA ($13.43), RSI(14) 20 (deeply oversold), MACD negative, −21% off the 52-wk high ($14.97); still +42% over 12 mo and above the 200-DMA ($11.07)
Gross margin keeps compressing (28.6% FY24 → 22.0% TTM → 15.9% in seasonally-weak Q1) while the reshaped portfolio's true earnings power is still unproven
One-line thesis. Ecovyst sold a major business in FY25 (~$527M of proceeds visible in the cash-flow statement), used the cash to wipe out what had been ~$900M of debt — FMP's TTM metrics now imply a roughly net-cash balance sheet — and the remaining sulfuric-acid-regeneration + catalyst company trades at ~13× FY27E earnings with a 6.7% FCF yield and five straight earnings beats; but gross margin is compressing, forward growth is only 4–6% once the FY26 base effect washes out, the Street's own $9.67 target sits below the price, and the stock has broken its uptrend (RSI 20) — so this is a Watch, not a buy, until the August 6 print shows the margin floor.
◆ Synthos call — WatchA newly de-levered sulfuric-acid and catalyst franchise at ~13x FY27 earnings with a 6.7% FCF yield — it gets interesting on a base near the 200-DMA (~$11) once the Aug-6 print confirms gross margin has stopped sliding; it breaks if margins keep compressing and the Street's $9.67 target proves right rather than stale.
Downside Risk (lower = safer)
6/10 · High
Beta 1.07 and a balance sheet that swung to roughly net cash after the FY25 divestiture are the brakes; against them a $1.3B small cap, thin 1-4-analyst coverage, gross margin down from 28.6% to 22.0%, a -33% max drawdown and refinery-cycle end markets.
Growth Quality
4/10 · Moderate
FY26E revenue +34% is portfolio reshaping, not organic — growth settles to 4-6% after; ROIC 3.8%, gross margin compressing, capex ~7.4% of revenue. Five straight EPS beats and ~26% estimated EPS CAGR off a depressed base keep it off a 3.
Exponential Potential
2/10 · Low
Revenue growth decelerates 34% -> 4% -> 6% across FY26E-FY28E — a GDP-plus industrial with self-help, not an exponential; no acceleration, modest TAM story.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Ecovyst is a 195-year-old industrial chemistry company with two jobs. First, it takes the used-up sulfuric acid that oil refineries need to make high-octane gasoline blendstock, cleans it, and sells it back — plus it sells fresh sulfuric acid to mining, water-treatment and industrial customers. Second, it makes specialty catalysts — the materials that make chemical reactions happen — for plastics production and for scrubbing pollution out of diesel exhaust.
In 2025 the company did a big spring-cleaning: it sold off a chunk of itself and used the money to pay down almost all of its debt. That matters — this used to be a heavily indebted business, and now it effectively owes nothing net of cash. The stock had a great year (+42%), but it has fallen hard over the last three months and the momentum gauges say it is as washed-out as it gets.
Here's what our three scores mean in everyday terms:
Downside Risk 6/10 (elevated, as most small caps are). The clean balance sheet and steady cash flow are real protection, but this is a $1.3B company covered by only a handful of analysts, its profit margin has been shrinking, and its customers are oil refineries — a cyclical, slowly-shrinking end market.
Growth Quality 4/10 (modest). The big revenue jump expected this year is mostly because the company changed shape, not because demand exploded. After that, growth settles to roughly the pace of the economy.
Exponential Potential 2/10 (low). This is a cash-generating industrial, not a multiplier. Nobody should own it hoping for a 5×.
The one big worry: the company keeps less of each sales dollar than it used to — gross margin has dropped meaningfully — and until a quarter or two proves that has stopped, the cheap-looking earnings multiple could be cheap for a reason.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLB (sector)), set to 100 a year ago
Solid = ECVT · dashed = S&P 500 · dotted = XLB (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$11.81
Market cap$1B
P/E trailing-21×
P/E FY26E / FY27E18× / 13×
EV / Sales1.4×
EV / EBITDA7.7×
Gross margin22.0%
Net margin-7.7%
Dividend yield0.00%
Beta1.069
52-wk range$8 – $15
RSI(14)20
50 / 200-DMA$13 / $11
12-mo return+42% (SPY +21%)
Street target$10 ($9–$10)
Analyst grades4 Buy · 2 Hold · 0 Sell
FMP ratingC+
Next earnings2026-08-05
What the experts actually said 0 traceable claims on ECVT · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
Ecovyst Inc. (NYSE: ECVT) is a specialty-chemicals company headquartered in Malvern, Pennsylvania — founded in 1831, renamed from PQ Group Holdings in August 2021, IPO 2017, CEO Kurt J. Bitting, ~920 employees. Two divisions:
Ecoservices — regenerates (recycles) spent sulfuric acid for refinery alkylate production and supplies virgin sulfuric acid for mining, water purification and industrial uses. This is the core: in the last year with clean segment data (FY22), Ecoservices was ~$702M of ~$820M revenue.
Catalyst Technologies — bespoke silica catalysts and process solutions for polyethylene and methyl-methacrylate producers, plus zeolite-based emission-control catalysts that strip NOx from diesel exhaust and sulfur from fuels (~$133M in FY22).
Geography: overwhelmingly domestic — FY24 filings show US $666M (95%) vs non-US $38M. This is a North American refinery-and-industrial services business, not a global chemical major.
The FY25 reshaping (visible in the statements, unnamed in our data file): FY25 shows a −$77.4M discontinued-operations loss, +$526.9M of net divestiture proceeds in investing cash flow, the ~$349M long-term JV investment coming off the balance sheet, $477M of debt paid down, and quarterly revenue stepping up ~40–50% YoY from Q2 2025. Our data file does not name the transaction counterparties, so we won't guess — but the shape is unambiguous: Ecovyst sold a business, killed its debt, and consolidated/expanded elsewhere. The FY26E revenue "growth" of +34% is this reshaping, not organic demand.
2. The expert thesis (traceable)
No expert-panel coverage — this note is fundamentals-driven. The Synthos KB contains zero traceable claims on ECVT (checked by ticker and by company name). That is the honest house standard for screen-surfaced names: no voices, no conviction rating, and no invented narrative. The stock entered our pipeline through the quantitative momentum screen (+42% over 12 months vs SPY +21%), and everything below reconciles to the FMP data file — filings-derived financials, live analyst estimates, and the technicals block. Where a bull case appears in this note, it is ours, built from the numbers, and labeled as such.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
6 · High
The brakes: beta 1.07, FMP TTM metrics implying net cash (net-debt/EBITDA −0.79×, EV $1.17B below the $1.29B market cap), current ratio 2.4×, FCF yield 6.7%. Against them: a $1.3B small cap with 1–4 analysts per out-year, gross margin down from 28.6% (FY24) to 22.0% TTM, a −33% max drawdown inside the past year, a 55% TTM effective tax rate, discontinued-ops noise across the FY25 statements, and refinery/alkylation end markets that are cyclical and structurally challenged long-term.
Growth Quality
4 · Moderate
FY26E revenue +34% is portfolio reshaping; organic growth thereafter is +4.2% (FY27E) and +5.9% (FY28E). ROIC 3.8% TTM, gross margin compressing, capex 7.4% of revenue. Credits: five straight EPS beats, ~26% estimated EPS CAGR FY26E→FY28E off a depressed base, and interest expense collapsing ($2.8M in Q1 2026 vs $6.2M a year earlier) as the debt paydown flows through.
Exponential Potential
2 · Low
Growth decelerates — 34% (reshaping) → 4% → 6%. No second-derivative story, no TAM inflection. A cash-yielding industrial with self-help, full stop.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path; the cases bound the range.
Case
Key assumptions
Fair value
Bull
Margins trough and rebuild; FY28E EPS $1.05 hits and the market pays ~14× for a net-cash, buyback-capable industrial; equivalently ~7× FY27E EBITDA ($233M) plus the cash.
~$15 (+27%)
Base(our anchor)
FY27E EPS ~$0.88 lands; a low-growth but de-levered, FCF-positive specialty chemical earns ~13.5× — roughly where it trades today.
~$12 (+2%)
Bear
Gross-margin compression persists into the reshaped portfolio; FY27 EPS misses toward ~$0.70 and the multiple stays ~12× — landing near the Street's own $9–10 target zone.
~$8.50 (−28%)
Synthos fair value = the base case, ~$12 (+2%). Two honest tensions, both flagged: (1) the Street consensus target is $9.67 — 18% below the price — yet the same analysts rate it 4 Buy / 2 Hold; targets from a 1–4-analyst pool after a +42% year are very likely stale, so we anchor on forward earnings power rather than adopting $9.67, but we show it prominently. (2) An EV/EBITDA cross-check (6.5–7× FY26E–FY27E EBITDA plus net cash) points higher, to ~$14–15 — that math is what keeps the bull case honest rather than heroic. FMP's own DCF sub-score is 5/5 (cheap on cash flow) even as its overall rating is a C+. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). ECVT is neither yet — it is a de-levered cash-yielder:
Forward growth: revenue FY26E $966.7M → FY27E $1,007.4M (+4.2%) → FY28E $1,066.6M (+5.9%). EPS $0.66 → $0.88 → $1.05 (~26% CAGR, but off a base depressed by the FY25 transition year).
Acceleration (the 2nd derivative) is negative: the +34% FY26E step is the portfolio change; underlying growth immediately settles to mid-single digits. This is the opposite of the profile that earns a high exponential score.
Room to run: modest. Sulfuric-acid regeneration is a regional, logistics-bound, quasi-utility business (a real moat — see §8) tied to refinery alkylation volumes; the catalyst arm serves mature plastics and diesel-emissions markets. There is no plausible TAM story that multiplies a $1.3B cap several-fold.
Reinvestment: capex runs ~7.4% of revenue (capex/depreciation 0.93×) — a maintenance-heavy asset base, not an asset-light scaler.
Exponential Potential: Low (2/10). Own it (if ever) for cash flow, balance-sheet optionality and re-rating — not for compounding magic.
Margins — the sore spot: gross margin 21.9% FY25 vs 28.6% FY24 and 28.6% FY23; TTM 22.0%. Q1 2026 gross margin was 15.9% — Q1 is seasonally weak (Q1 2025 was 11.9%), but the annual trend is down. EBITDA margin 18.5% TTM; operating margin 11.8% TTM.
Earnings — read carefully: FY25 bottom-line net income was −$71.1M (EPS −$0.61), but −$77.4M of that was discontinued operations; continuing operations earned +$6.3M. Q1 2026: GAAP diluted EPS $0.04, adjusted EPS $0.11 (vs $0.07 est). The GAAP tax line is ugly — FY25 effective rate ~76% ($19.5M tax on $25.8M pretax), TTM ~55%. Income-quality ratio is −2.2 (negative GAAP income, positive cash flow) — cash tells the truer story here.
Balance sheet — the transformation: FY23 total debt $900M / net debt $812M → FY25 year-end total debt $430.7M / net debt $233.5M (1.7× FY25 EBITDA) → and FMP's TTM ratios (which use the Q1 2026 balance sheet) imply total debt ~$43M, cash ~$163M — i.e., ~$119M net cash (net-debt/EBITDA −0.79×, debt/equity 0.075). The FY25 divestiture proceeds went to debt elimination. Goodwill + intangibles are $386M, 31% of assets — moderate. We flag the annual-vs-TTM balance-sheet gap explicitly; both figures are from the same file.
6. Valuation — priced in or room?
Trailing multiples are noise here (FMP prints ~82× TTM P/E on depressed continuing EPS; TTM net income is negative on a GAAP bottom-line basis). The real question is forward: 17.8× FY26E ($0.66) → 13.4× FY27E ($0.88) → 11.2× FY28E ($1.05), EV/EBITDA 7.7× TTM falling to ~5.2× FY26E ($224M) on the current EV, EV/sales 1.4×, price/book 2.3×, FCF yield 6.7%. For a net-cash industrial with a quasi-utility core, that is inexpensive-to-fair — FMP's DCF sub-score of 5/5 agrees, while its overall C+ rating (ROE 1/5, P/E 1/5) reflects the messy GAAP year. The Street contradiction, shown honestly: consensus target $9.67 (high $10 / low $9) is 18% below the price while ratings are 4 Buy / 2 Hold — with only 1–4 analysts contributing estimates per year, we read the targets as stale rather than prophetic, but a thin-coverage name where the printed targets say "down 18%" does not get a Buy tier from us on valuation alone. Not priced for perfection; priced for proof.
7. Technicals (from the tech block)
Trend: broken near-term. $11.81 is 12% below the 50-DMA ($13.43) and only ~7% above the 200-DMA ($11.07). MACD −0.39 (negative).
Location:−21% off the 52-week high ($14.97), +51% off the 52-week low ($7.84); max drawdown from peak inside the year was −33%.
Momentum: RSI(14) 20 — deeply oversold, the kind of washed-out reading that precedes either a bounce or a thesis change.
Relative strength (the tell): +42.3% over 12 months (SPY +21.1%, QQQ +31.2%) and +21.4% over 6 months (SPY +10.2%) — but −9.4% over 3 months vs SPY +14.6%: a 24-point relative-strength collapse this quarter. The market is repricing something.
Read: a 12-month winner in a sharp correction, now sitting just above its 200-DMA with momentum flushed. For a Watch name this is exactly the setup to monitor: a hold of the ~$11 zone (200-DMA) plus a margin-confirming Q2 print is the trigger; a decisive break below it says the bear case is taking over.
8. Moat & competitive position
The Ecoservices core has a genuinely defensible franchise: sulfuric-acid regeneration is a logistics-bound, site-adjacent, permit-heavy service — spent acid is hazardous and uneconomic to ship far, so regeneration contracts with refineries are sticky, regional, and hard for a new entrant to attack. That is a quasi-utility moat. The Catalyst Technologies arm sells specified-in products (polyethylene/MMA catalysts, zeolite emission-control) where qualification cycles create switching costs. The limits: the moat guards a slow pond — alkylate demand rides gasoline consumption, which is structurally flat-to-declining long-term; ROIC of 3.8% TTM says the moat is not currently producing elite economics (though the FY25 reshaping muddies that measure).
Peer set (FMP-supplied, market cap): a grab-bag rather than clean comps — ASP Isotopes $0.5B, Braskem $1.0B, Collective Mining $1.3B, Green Plains $1.1B, Ferroglobe $0.6B, Lightwave Logic $1.1B, McEwen Mining $1.1B, Oil-Dri $1.4B, REX American $1.5B, Stepan $1.3B. Only Stepan (and loosely Oil-Dri) are relevant specialty-chemical comparators; judge ECVT against specialty-chem/industrial-services names, not this list. Data caveat flagged.
9. Management, capital allocation & guidance
Capital allocation — the FY25 story is the headline: ~$527M of divestiture proceeds → $477M of debt paydown in one year, taking net debt from $753M (FY24) to $233M at year-end and to roughly net cash by Q1 2026 per the TTM ratios. Alongside: $46.9M of buybacks in FY25 ($136.7M in FY22, $78.7M in FY23) — share count is down from ~136M (FY21) to ~110.7M (Q1 2026), a ~19% reduction. No dividend. For a small-cap industrial, that is disciplined, shareholder-oriented allocation.
Insider activity: nothing discretionary in the file — recent Form 4s are director/officer RSU awards (Feb–May 2026) and a CEO option exercise (M-Exempt, March 2026, exercise price $3.04). No open-market buys or sells either way — neutral signal, worth noting that no insider has bought the −33% dip with cash.
Guidance: our data file contains no management-guidance block for ECVT (no KB ingestion for this name). What we can verify: the company has beaten the Street's EPS estimate five quarters running (Q1'25 through Q1'26, including $0.29 vs $0.15 in Q4'25 and $0.11 vs $0.07 in Q1'26). Estimate-beating cadence is a fact; forward guidance is a gap we flag rather than fill.
10. Catalysts & what to watch
Next earnings: 2026-08-06 (Q2 2026; Street EPS $0.19, revenue ~$237.5M). The key line: gross margin — Q2'25 was 23.5%; a print at or above that says the compression was mix/transition noise, a print below ~22% says it's structural.
Post-divestiture earnings power: the first full clean year of the reshaped portfolio (FY26E EPS $0.66) — every quarter that reconciles toward it de-risks the 13× FY27 multiple.
Balance-sheet deployment: with ~net cash and $70M+ of annual FCF, watch for a resumed/enlarged buyback or a bolt-on — either would be the natural next move given the FY22–FY25 pattern.
Analyst re-initiation: coverage is 1–4 analysts per out-year with visibly stale targets; fresh targets after the Q2 print could re-anchor the stock either way.
Refinery-utilization / alkylation demand data: the Ecoservices core rides it.
Thesis tripwires (what would change the call): gross margin below ~22% for two consecutive quarters; a decisive weekly close below the 200-DMA (~$11); FY27 consensus EPS revised below ~$0.75; or leverage re-appearing for a large acquisition.
11. Key risks
Margin compression (the dominant risk): gross margin 28.6% → 21.9% in one year; if the reshaped portfolio is structurally lower-margin, the FY27–FY28 EPS estimates — built by very few analysts — are too high.
Thin coverage / stale-signal risk: 1–4 analysts, a $9.67 consensus target below the market price, and a 1-analyst FY28 EPS number: the "cheap forward multiple" rests on a narrow estimate base.
End-market structure: refinery alkylation is tied to gasoline demand — cyclical now, secularly shrinking later. The moat is real but the pond is not growing.
Transition-year opacity: FY25 GAAP is littered with discontinued ops, a 76% effective tax rate and divestiture effects; underwriting clean earnings power requires two or three more clean quarters.
Small-cap liquidity: ~$1.3B cap, ~2M shares average daily volume — exits are cheap until everyone wants one.
Technical breakdown: the 3-month tape (−9% vs SPY +15%) says someone is selling with conviction; RSI 20 can stay oversold in a genuine de-rating.
12. Verdict, position sizing & monitoring
Watch. The transformation is real and verifiable in the statements: a business sold, ~$900M of debt taken to roughly net cash, share count down 19% since 2021, five straight beats, a 6.7% FCF yield, and a defensible quasi-utility core — at 13.4× FY27E earnings that is a credible value-with-a-catalyst setup. But we don't get paid to anticipate proof we can have in five weeks: gross margin is still falling, the Street's printed targets sit 18% below the price, coverage is too thin to lean on, and the price action has broken (RSI 20, price below the 50-DMA). The trigger: a Q2 2026 print (Aug 6) with gross margin ≥ ~23% and the FY26 EPS path intact, with the stock basing at or above the ~$11 200-DMA zone — that combination upgrades this to a tactical buy candidate. A margin miss or a decisive break of $11 sends it toward the bear case and off the list.
Sizing: none today. If triggered, satellite ~1–2% — small-cap sleeve sizing, sized so a one-third drawdown (already demonstrated this year) is survivable.
Monitoring: §10 tripwires; formal re-score at the 2026-08-06 print. This Watch is logged as a tracked Synthos call as of 2026-07-06 at $11.81.
Single biggest risk: the margin slide proves structural, turning a cheap-looking 13× into a fair 13× on falling estimates.
Provenance & disclosures
Traceability:0 KB claims, 0 voices — no expert-panel coverage of ECVT exists in the Synthos knowledge base (verified by ticker and company-name search). Conviction rating is therefore None and no expert narrative appears in this note; fabricated conviction is structurally impossible (claim-ID reconciliation), and the honest handling of an empty panel is to say so.
Data as-of: fundamentals 2026-03-31 (Q1 2026, filed 2026-05-05) · estimates & prices 2026-07-06 (FMP) · KB claims: none. Forward figures are analyst consensus (FMP) from a thin pool (1–4 analysts per year), labeled as estimates.
Transaction caveat: the FY25 divestiture/reshaping is described strictly from statement mechanics (discontinued ops, $527M investing inflow, JV investment removal, $477M debt paydown); the data file does not name the counterparties, so this note doesn't either.
Balance-sheet caveat: the FY25 annual balance sheet shows $233.5M net debt; FMP's TTM ratio block (Q1 2026 basis) implies ~$119M net cash. Both are reported; the TTM figure is the fresher one.
Guidance caveat: no management-guidance ingestion for ECVT; the beat streak is from the FMP earnings calendar, not company commentary.
Peer caveat: the FMP-supplied peer list is largely irrelevant (miners, ethanol, photonics); Stepan is the only clean specialty-chem comp shown.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-06. Prior versions available via the deep-dive version dropdown ("based on the info at the time").